Foundations acquire a critical new role as federal funding for cancer research falters

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The fight against cancer is complex. It’s global. And it’s indisputably expensive. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Ryan Schoenfeld, PhD
CEO, The Mark Foundation
Raymond N. DuBois, MD, PhD
Executive chair of the board, The Mark Foundation; Director, Medical University of South Carolina Hollings Cancer Center; Past dean of Medicine, the Medical University of South Carolina
Table of Contents

YOU MAY BE INTERESTED IN

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31. 
As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
Ryan Schoenfeld, PhD
CEO, The Mark Foundation
Raymond N. DuBois, MD, PhD
Executive chair of the board, The Mark Foundation; Director, Medical University of South Carolina Hollings Cancer Center; Past dean of Medicine, the Medical University of South Carolina

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login